Status:

RECRUITING

Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)

Lead Sponsor:

Massachusetts General Hospital

Conditions:

CHF

ADHF

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blo...

Detailed Description

The primary objective of this study is to investigate the expression of extracellular vesicle RNAs (evRNAs) during admission for and decongestion of ADHF patients and determine their diagnostic and pr...

Eligibility Criteria

Inclusion

  • Inclusion Criteria CHF:
  • At least 18 years of age
  • Stable disease defined as CHF of any type, New York Heart Association (NYHA) functional class II/III/IV, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥600 pg/ml if Left Ventricular Ejection Fraction (LVEF) ≤30%; ≥1000 pg/mL if LVEF 31-35%; ≥2500 pg/mL if EF \>35%
  • Inclusion Criteria ADHF:
  • At least 18 years of age
  • Clinical signs and/or symptoms (including exertional or rest dyspnea, orthopnea or Paroxysmal Nocturnal Dyspnea (PND)) and N-terminal pro-BNP level \> 1000 pg/mL or BNP \> 400 pg/ml, OR Clinical evidence of congestion: X-ray evidence of pulmonary edema or pleural effusions, elevated Jugular Venous Pulse (JVP), lower extremity edema, or rales on pulmonary examination, right heart catheterization evidence of elevated filling pressures (Right Atrium (RA) pressure \> 10 mmHg; Pulmonary Capillary Wedge Pressure (PCWP) \> 18 mmHg) and clinical response to Intravenous (IV) diuretic therapy (as judged by a physician)
  • Inclusion Criteria control:
  • At least 18 years of age
  • Will/have undergone an EP procedure in the EP lab
  • Exclusion Criteria:
  • Active pregnancy or lactation
  • Cardiac amyloidosis
  • Active malignancies

Exclusion

    Key Trial Info

    Start Date :

    April 19 2023

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2027

    Estimated Enrollment :

    90 Patients enrolled

    Trial Details

    Trial ID

    NCT06169540

    Start Date

    April 19 2023

    End Date

    December 31 2027

    Last Update

    November 13 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114

    Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF) | DecenTrialz